Search results
Results From The WOW.Com Content Network
It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. [4] [5] It is only recommended when other options are not appropriate. [4] It is given by infusion into a vein. [4] Common side effect include nausea, fever, liver problems, headache, trouble sleeping, and pain at the site of infusion. [4]
Indicated for complicated skin/skin structure infections, soft tissue infections and complicated intra-abdominal infections. Effective for gram-positive, gram-negative, anaerobic, and against multi-antibiotic resistant bacteria (such as Staphylococcus aureus [MRSA] and Acinetobacter baumannii ), but not effective for Pseudomonas spp. and ...
It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. [ 2 ] [ 7 ] It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. [ 2 ]
Uncomplicated infections often involved the infection of single organ and can be controlled by surgical removal of the source of infection, and antibiotics is not required after the surgery to control the infection. In complicated infections, the infection spread to a part or to the whole of the peritoneum, causing peritonitis. Meanwhile ...
Secondary peritonitis and intra-abdominal abscesses including splenic and hepatic abscesses generally occur because of the entry of enteric micro-organisms into the peritoneal cavity through a defect in the wall of the intestine or other viscus as a result of obstruction, infarction or direct trauma.
Mycobacterium avium-intracellulare infection (MAI) is an atypical mycobacterial infection, i.e. one with nontuberculous mycobacteria or NTM, caused by Mycobacterium avium complex (MAC), which is made of two Mycobacterium species, M. avium and M. intracellulare. [1]
Avibactam is a non-β-lactam β-lactamase inhibitor [2] developed by Actavis (now Teva) jointly with AstraZeneca.A new drug application for avibactam in combination with ceftazidime was approved by the FDA in 2015 for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic-resistant pathogens, including those caused by multidrug ...
Aztreonam/avibactam, sold under the brand name Emblaveo, is a fixed-dose combination antibacterial medication used for the treatment of aerobic Gram-negative infections. [4] It is a combination of aztreonam, a monobactam antibacterial; and avibactam, a beta-lactamase inhibitor. [4] It was developed by AbbVie and Pfizer. [4] [5] [6]